ANDA 77-091



OFFICE OF GENERIC DRUGS

Food and Drug Administration HFD-600, Metro Park North II 7500 Standish Place, Room 150 Rockville, MD 20855-2773 Fax: 301-594-0180

FAX TRANSMISSION COVER SHEET

APPLICANT: Dr. Reddy's Laboratories Inc.,

U.S. Agent for Dr. Reddy's Laboratories Limited

ATTN: Kumara Sekar

TEL: 908-203-4937

FAX: 908-203-4980

FROM: Peter Chen

PROJECT MANAGER: (301) 827-5773


Dear Sir:

This facsimile is in reference to your abbreviated new drug application dated March 17, 20054, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Glimepiride Tablets, 1 mg, 2 mg, and 4 mg.

We are pleased to inform you that this application is APPROVED!

THIS DOCUMENT IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, OR PROTECTED FROM DISCLOSURE UNDER APPLICABLE LAW.

If received by someone other than the addressee or a person authorized to deliver this document to the addressee, you are hereby notified that any disclosure, dissemination, copying, or other action to the content of this communication is not authorized. If you have received this document in error, please immediately notify us by telephone and return it to us by mail at the above address.



DEPARTMENT OF HEALTH & HUMAN SERVICES

ANDA 77-091

Food and Drug Administration Rockville MD 20857

6 2005 CT

Dr. Reddy's Laboratories, Inc. Attention: Kumara Sekar, Ph.D. Director, Global Regulatory Affairs U.S. Agent for: Dr. Reddy's Laboratories Limited 200 Somerset Corporate Blvd., 7th Floor Bridgewater, NJ 08807

Dear Sir:

This is in reference to your abbreviated new drug application (ANDA) dated March 17, 2004, submitted pursuant to Section 505(i) of the Federal Food, Drug, and Cosmetic Act (the Act), for Glimepiride Tablets, 1 mg, 2 mg, and 4 mg.

Reference is also made to the tentative approval letter issued by this office on August 18, 2005; and to your amendments dated March 31, June 8, June 10, September 6, and September 23, 2005.

The listed drug product (RLD) referenced in your application, Amaryl Tablets of Aventis Pharmaceuticals Inc., has been subject to a period of patent protection. As noted in the agency's publication entitled Approved Drug Products with Therapeutic Equivalence Evaluations, the "Orange Book", U.S. Patent No. 4,379,785 (the '785) expired on October 6, 2005 (pediatric extension).

With the expiration of the '785 patent, we have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the application is approved. The Division of Bioequivalence has determined your Glimepiride Tablets, 1 mg, 2 mg, and 4 mg, to be bioequivalent and, therefore, therapeutically equivalent to the listed drug (Amary) Tablets, 1 mg, 2 mg, and 4 mg, respectively, of Aventis Pharmaceuticals Inc.). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.

Under Section 506A of the Act, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.

Postmarketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert(s) directly to:

Food and Drug Administration Center for Drug Evaluation and Research Division of Drug Marketing, Advertising, and Communications 5901-B Ammendale Road Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Division of Drug Marketing, Advertising, and Communications (HFD-42) with a completed Form FDA 2253 at the time of their initial use.

Sincerely yours,

Army Brehl

Gary Buehler

Director

Office of Generic Drugs

Center for Drug Evaluation and Research